Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

The nocebo effect is under-recognised in the era of biosimilars, although it may negatively impact on the cost-savings of biosimilars. Future research should focus on the magnitude, the risk factors, the impact, and the management of the nocebo effect in biosimilars-treated IBD patients.